MTDH and head and neck squamous cell carcinoma: These findings may support the development of AEG-1-targeting therapeutics, such as small molecules, interference RNA with suitable drug delivering system or DNA vaccine, [50] to bolster our arsenal of adjuvant chemotherapy, and thereby improving the clinical outcome of HNSCC patients with high AEG-1 expression.